Callio Therapeutics logo

Callio Therapeutics

calliotx.com

Callio Therapeutics develops dual-payload antibody-drug conjugates (ADCs) for people with cancer, including patients with tumors that have developed resistance to existing therapies. Its platform pairs synergistic drug payloads and uses a proprietary linker to design targeted treatments intended to overcome resistance and deliver more durable responses.

Facts

HQ
Seattle, WA, USA
Sectors
Biotechnology Research
Founded
2025
Employees
24
Stage
Series A

Is this your organization? Claim it

People

See all 8
  • Jerome Boyd-Kirkup Co-Founder
  • Piers Ingram Co-Founder
  • Chris Hassig Executive, Chief Scientific Officer

Online